Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma

Clinical Cancer Research

Volumn 20, Issue 9, 2014, Pages 2457-2465

  Chodon, Thinle ^a,l   Comin Anduix, Begoña ^a,b   Chmielowski, Bartosz ^a,b   Koya, Richard C ^a,b,l   Wu, Zhongqi ^a   Auerbach, Martin ^b   Ng, Charles ^a   Avramis, Earl ^a   Seja, Elizabeth ^a   Villanueva, Arturo ^a   McCannel, Tara A ^c   Ishiyama, Akira ^a   Czernin, Johannes ^b   Radu, Caius G ^b   Wang, Xiaoyan ^a   Gjertson, David W ^a   Cochran, Alistair J ^a   Cornetta, Kenneth ^h   Wong, Deborah J L ^a   Kaplan Lefko, Paula ^a   Hamid, Omid ^e   Samlowski, Wolfram ⁱ   Cohen, Peter A ^j   Daniels, Gregory A ^f   Mukherji, Bijay ^k   Yang, Lili ^a,b,d   Zack, Jerome A ^a,b,d   Kohn, Donald B ^a,b,d   Heath, James R ^g   Glaspy, John A ^a,b   Witte, Owen N ^a,b,d   Baltimore, David ^g   Economou, James S ^a,b   Ribas, Antoni ^a,b,d   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c JULES STEIN EYE INSTITUTE   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e Angeles Clinic and Research Institute   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

^h INDIANA UNIVERSITY   (United States)

ⁱ Department of Hematology Oncology   (United States)

^j MAYO CLINIC   (United States)

^k UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^l ROSWELL PARK CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMG 337; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; FLUDARABINE; GLEMBATUMUMAB; IPILIMUMAB; MELAN A; PACLITAXEL; PEVONEDISTAT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; T LYMPHOCYTE RECEPTOR; TEMOZOLOMIDE; UNCLASSIFIED DRUG; CANCER VACCINE; LYMPHOCYTE ANTIGEN RECEPTOR; PEPTIDE FRAGMENT;

ADOPTIVE TRANSFER; ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CRYOPRESERVATION; DENDRITIC CELL; FEMALE; GENE TRANSFER; GENETIC ENGINEERING; HUMAN; IN VIVO STUDY; MALE; METASTATIC MELANOMA; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR REGRESSION; ADOPTIVE IMMUNOTHERAPY; ADVERSE EFFECTS; CANCER STAGING; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; GENETIC TRANSDUCTION; GENETICS; IMMUNOLOGY; MELANOMA; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; TREATMENT OUTCOME; VACCINATION;

ADULT; CANCER VACCINES; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MALE; MART-1 ANTIGEN; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PEPTIDE FRAGMENTS; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES; TOMOGRAPHY, X-RAY COMPUTED; TRANSDUCTION, GENETIC; TREATMENT OUTCOME; VACCINATION;

EID: 84899731823     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-3017     Document Type: Article

References (34)

1. Dembic Z, Haas W, Zamoyska R, Parnes J, Steinmetz M, von Boehmer H. Transfection of the CD8 gene enhances T-cell recognition. Nature 1987;326:510-1.
2. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006;314:126-9.
3. Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009;114:535-46.
4. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. Am J Clin Oncol 2011;29:917-24.
5. Johnson LA, Heemskerk B, Powell DJ Jr, Cohen CJ, Morgan RA, Dudley ME, et al. Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. J Immunol 2006;177:6548-59.
6. Klebanoff CA, Gattinoni L, Torabi-Parizi P, Kerstann K, Cardones AR, Finkelstein SE, et al. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A 2005;102:9571-6.
7. Klebanoff CA, Gattinoni L, Restifo NP. CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev 2006;211:214-24.
8. Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, de Jong LA, Vyth-Dreese FA, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 2003;198:569-80.
9. Lou Y,Wang G, Lizee G, Kim GJ, Finkelstein SE, Feng C, et al. Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo. Cancer Res 2004;64:6783-90.
10. Koya RC, Mok S, Comin-Anduix B, Chodon T, Radu CG, Nishimura MI, et al. Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses. Proc Natl Acad Sci U S A 2010;107:14286-91.
11. Borrello I, Sotomayor EM, Rattis FM, Cooke SK, Gu L, Levitsky HI. Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines. Blood 2000;95: 3011-9.
12. Cui Y, Kelleher E, Straley E, Fuchs E, Gorski K, Levitsky H, et al. Immunotherapy of established tumors using bone marrow transplantation with antigen gene-modified hematopoietic stem cells. Nat Med 2003;9:952-8.
13. Butterfield LH, Ribas A, Dissette VB, Amarnani SN, Vu HT, Oseguera D, et al. Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res 2003;9:998-1008.
14. Ribas A, Glaspy JA, Lee Y, Dissette VB, Seja E, Vu HT, et al. Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy. J Immunother 2004;27:354-67.
15. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-10.
16. Figlin R, Gitlitz B, Franklin J, Dorey F, Moldawer N, Rausch J, et al. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients. Cancer J Sci Am 1997;3 Suppl 1:S92-7.
17. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298:850-4.
18. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
19. Comin-Anduix B, Gualberto A, Glaspy JA, Seja E, Ontiveros M, Reardon DL, et al. Definition of an immunologic response using the major histocompatibility complex tetramer and enzyme-linked immunospot assays. Clin Cancer Res 2006;12:107-16.
20. Comin-Anduix B, Lee Y, Jalil J, Algazi A, de la Rocha P, Camacho LH, et al. Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma. J Transl Med 2008;6:22.
21. Murali-Krishna K, Altman JD, Suresh M, Sourdive DJ, Zajac AJ, Miller JD, et al. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity 1998;8:177-87.
22. Ma C, Cheung AF, Chodon T, Koya RC, Wu Z, Ng C, et al. Multifunctional T-cell analyses to study response and progression in adoptive cell transfer immunotherapy. Cancer Discov 2013;3:1-12.
23. Kwong GA, Radu CG, Hwang K, Shu CJ, Ma C, Koya RC, et al. Modular nucleic acid assembled p/MHC microarrays for multiplexed sorting of antigen-specific T cells. J Am Chem Soc 2009;131:9695-703.
24. Ma C, Fan R, Ahmad H, Shi Q, Comin-Anduix B, Chodon T, et al. A clinical microchip for evaluation of single immune cells reveals high functional heterogeneity in phenotypically similar T cells. Nat Med 2011;17:738-43.
25. Quezada SA, Simpson TR, Peggs KS, Merghoub T, Vider J, Fan X, et al. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. Jpn J Exp Med 2010;207:637-50.
26. Araki K, Turner AP, Shaffer VO, Gangappa S, Keller SA, Bachmann MF, et al. mTOR regulates memory CD8 T-cell differentiation. Nature 2009;460:108-12.
27. Li Q, Rao RR, Araki K, Pollizzi K, Odunsi K, Powell JD, et al. A central role for mTOR kinase in homeostatic proliferation induced CD8+ T cell memory and tumor immunity. Immunity 2011;34:541-53.
28. Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, et al. A human memory T cell subset with stem cell-like properties. Nat Med 2011; 17:1290-7.
29. Yang L, Qin XF, Baltimore D, Van Parijs L. Generation of functional antigen-specific T cells in defined genetic backgrounds by retrovirusmediated expression of TCR cDNAs in hematopoietic precursor cells. Proc Natl Acad Sci U S A 2002;99:6204-9.
30. Yang L, Baltimore D. Long-term in vivo provision of antigen-specific T cell immunity by programming hematopoietic stem cells. Proc Natl Acad Sci U S A 2005;102:4518-23.
31. Vatakis DN, Koya RC, Nixon CC, Wei L, Kim SG, Avancena P, et al. Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells. Proc Natl Acad Sci U S A 2011;108:E1408-16.
32. Morgan RA, Yang JC, Kitano M, Dudley ME, LaurencotCM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010;18:843-51.
33. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006;355:1018-28.
34. Endeman H, Meijvis SC, Rijkers GT, van Velzen-Blad H, van Moorsel CH, Grutters JC, et al. Systemic cytokine response in patients with community-acquired pneumonia. Eur Respir J 2011;37:1431-8.